Summit Therapeutics Shares Drop 11% on $500M Offering Despite Strong Ivonescimab 24-Month OS Data
SMMT is trading near its 52-week low of $12.55 (4.4% above the low) on elevated volume (1.9× avg).
Summary
Summit Therapeutics reported strong 24-month Overall Survival (OS) data for its lead drug ivonescimab, showing 64.7% OS versus 48.6% for a comparator in a late-stage NSCLC trial. This positive clinical update builds on earlier Phase III results for ivonescimab announced on June 1st. Concurrently, the company announced a $500 million secondary common stock offering, which was previously disclosed in a June 9th 424B5 filing. The offering represents a material dilution of approximately 5% of the company's market cap. Despite the encouraging drug data, shares fell 11% intraday, indicating the market's immediate focus on the dilutive financing.
At the time of this announcement, SMMT was trading at $13.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.1B. The 52-week trading range was $12.55 to $30.98. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Wiseek News.